50 ML Itraconazole Oral Solution

Product Name: Itraconazole Oral Solution

Ingredient: Itraconazole

Appearance: Light brown to brown clear liquid.

Pharmacological Effects:

Itraconazole exerts its antifungal effect by inhibiting the activity of fungal cytochrome P450 dependent sterol 14α-demethylase, thereby blocking the synthesis of ergosterol (a key component of the fungal cell membrane), inhibiting fungal proliferation and promoting fungal death.Its major metabolite, hydroxyitraconazole, also exhibits equivalent antifungal activity. It is active against dermatophytes (Trichophyton spp, Microsporum spp), yeasts (Candida spp, Malassezia spp.), various dimorphic fungi and zygomycetes.

Drug Interactions:

1.This product exhibits maximum absorption in an acidic environment. Therefore, antacids, proton pump inhibitors ( omeprazole), H2-receptor antagonists ( cimetidine, ranitidine), or didanosine can significantly reduce the absorption of itraconazole. Didanosine must not be administered concurrently with itraconazole. If necessary, other drugs (as mentioned above) should only be taken 2 hours after itraconazole administration.

2.This product may prolong the clotting time in animals receiving warfarin or other coumarin anticoagulants. Rifampin may increase the metabolism of itraconazole, requiring adjustment of the itraconazole dosing regimen.

3.This product may decrease the metabolism of phenytoin or cyclosporine.

4.This product may increase plasma digoxin concentrations; therefore, plasma digoxin levels should be monitored.

5.This product may increase plasma levels of oral antidiabetic drugs (e.g., chlorpropamide, glipizide), potentially leading to hypoglycemia.

6.Concomitant administration with cisapride, ketoconazole, miconazole, or triacetylleucomycin may increase cisapride concentrations, which can subsequently cause arrhythmias.

Indications:

Primarily indicated for feline dermatophytosis caused by susceptible fungi such as Microsporum canis.

Dosage and Administration:

Calculated based on this product. Administer orally on an empty stomach, slowly injecting the liquid into the oral cavity using a dosing syringe: 0.5 mL per kg body weight in cats, once daily. Administer for 7 consecutive days, followed by a 7-day discontinuation period, constituting one cycle. Typically, 3 cycles are used.

Adverse Reactions:

1.Hepatotoxicity (approximately 13%): Including mild elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), jaundice, etc.

2.Gastrointestinal reactions (approximately 3%): Including diarrhea, vomiting, weight loss, which may lead to hypersalivation, anorexia, etc.

3.Neurological/behavioral reactions (approximately 1%): Including lethargy, fatigue, drowsiness, etc.

Precautions:

1.Use at the recommended dosage. Do not exceed the recommended dose, especially in kittens.

2.Cats with immunodeficiency or other concurrent diseases should be closely monitored during treatment.

3.Contraindicated in cats with impaired liver or renal function.

4.Contraindicated in pregnant or lactating cats.

5.Discontinue administration if abnormal liver function or liver injury is observed after dosing.

6.This product is a cytochrome p-450 inhibitor, which may increase or prolong the plasma concentrations of other drugs metabolized via this pathway, such as amitriptyline, amlodipine, benzodiazepines, buspirone, cisapride, corticosteroids, cyclosporine, ivermectin, and macrolide antibiotics.

Specification:1%

Package: 50ml/bottle,1bottle/box

Storage:Store tightly sealed.

Shelf Life:48 months